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Limb-girdle muscular dystrophy 2I (LGMD2I) is
caused by mutations in the fukutin-related protein
(FKRP) gene. Unlike its severe allelic forms, LGMD2I
usually involves slower onset and milder course with-
out defects in the central nervous system. The lack of
viable animal models that closely recapitulate
LGMD2I clinical phenotypes led us to use RNA inter-
ference technology to knock down FKRP expression
via postnatal gene delivery so as to circumvent em-
bryonic lethality. Specifically, an adeno-associated vi-
ral vector was used to deliver short hairpin (shRNA)
genes to healthy ICR mice. Adeno-associated viral vec-
tors expressing a single shRNA or two different shR-
NAs were injected one time into the hind limb mus-
cles. We showed that FKRP expression at 10 months
postinjection was reduced by about 50% with a single
shRNA and by 75% with the dual shRNA cassette. Du-
al-cassette injection also reduced a-dystroglycan gly-
cosylation and its affinity to laminin by up to 70% and
induced -dystrophic pathology, including fibrosis
and central nucleation, in more than 50% of the myo-
fibers at 10 months after injection. These results sug-
gest that the reduction of approximately or more than
75% of the normal level of FKRP expression induces
chronic dystrophic phenotypes in skeletal muscles.
Furthermore, the restoration of about 25% of the
normal FKRP level could be sufficient for LGMD2Itherapy to correct the genetic deficiency effectively
and prevent dystrophic pathology. (Am J Pathol
2011, 178:261–272; DOI: 10.1016/j.ajpath.2010.11.020)
Limb-girdle muscular dystrophies (LGMD) are a group of
clinically and genetically heterogeneous muscular dis-
eases that have both autosomal dominant (type 1) and
autosomal recessive (type 2) inheritance. The disorders
are generally characterized by progressive muscle wast-
ing and weakness of the shoulder and pelvic girdles and
often are associated with a wide range of clinical sever-
ity.1–5 To date, at least 13 subtypes (A–M) of LGMD type
2 have been reported, and the causative genes for
each subtype have also been identified; LGMD2I
(OMIM_607155) is one of the subsets and is caused by
mutations in the gene encoding fukutin-related protein
(FKRP). The disease is also one of the more common
types of LGMD in Denmark,6 the United Kingdom,7 Bra-
zil,8 and the United States.9,10 The onset of LGMD2I can
occur from early childhood to adulthood. In addition,
cardiac involvement has been frequently reported in pa-
tients with LGMD2I.6,7,11–13 By far, the most common
mutation in the FKRP gene is the point mutation C826A in
the coding sequence, which results in an amino acid
change from leucine to isoleucine (L276I) at position
276.6–10 Several studies have reported that homozygous
L276I mutation is generally associated with a mild phe-
notype, whereas compound heterozygous mutation
tends to produce a more severe course.6,14–16 Currently,
the diagnosis for LGMD2I is based mainly on clinical
evaluations and immunohistochemical analyses of mus-
cle biopsies followed by genetic screening for the FKRP
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diovascular magnetic resonance imaging.11
The human FKRP gene is mapped to chromosome
19q13.3 and consists of four exons,19 with exon 4 being
the single coding exon. The FKRP transcript is expressed
predominantly in the skeletal muscle, placenta, and
heart.20 The FKRP protein has been shown to localize to
the Golgi apparatus,21–24 but other studies have reported
its localization to the endoplasmic reticulum25 and sarco-
lemma.26 Although the precise function of FKRP is not
clearly understood, evidence strongly suggests that the
protein is involved in post-translational modification of
E-dystroglycan,16,26–28 a critical component of the dys-
trophin-glycoprotein complex at the sarcolemma.29 For
example, mutations in the FKRP gene are often associ-
ated with secondary abnormal glycosylation of -dystro-
glycan (hypoglycosylation)20,30–33 and can cause more
severe types of muscular dystrophies, including Walker-
Warburg syndrome, muscle-eye-brain disease,34 and
congenital muscular dystrophy type 1C.20,35
Although recent clinical studies have made rapid
progress in understanding LGMD2I, the lack of a viable
animal model for LGMD2I has impeded research into its
pathobiology and the development of therapeutics. Tar-
geted deletion of the mouse FKRP gene was embryoni-
cally lethal, indicating that FKRP is required for embryo
development (unpublished results, Q.L.L.). In humans,
no patient has ever been reported to carry homozygous
null mutations of the FKRP gene until recently. Dr. van
Reeuwijk and colleagues reported that two siblings car-
rying a homozygous mutation (c.1 AG, Met1Val) in the
start codon of FKRP resulted in Walker-Warburg syn-
drome, the most severe disorder in the disease spectrum
of dystroglycanopathies.36 This is highly likely to be a
homozygous null FKRP mutation. On the other hand, ex-
periments in our own laboratory and others showed that
mice engineered homozygous for the mild L276I mis-
sense mutation in the FKRP gene exhibited no apprecia-
ble phenotypes (unpublished observations). Recently,
Ackroyd and colleagues37 reported that knockin mice
carrying a disease-causing Y307N mutation in the FKRP
gene also failed to generate discernible phenotypes. It is
interesting to note that if the neomycin-resistant cassette
was kept in the mutant FKRP allele, the homozygous
Y307N neo mice developed very severe phenotypes,
including abnormalities in muscle, eye, and brain, and
died immediately after birth. In addition, the levels of
FKRP transcripts and -dystroglycan glycosylation (-
DG) were reduced. These results suggest that a knock-
down strategy might be a good alternative for investigat-
ing FKRP functions. In support of this idea, it has been
demonstrated that down-regulation of FKRP has led to
developmental abnormalities in zebrafish morphant em-
bryos.38,39 There is still a need for the generation of a
viable LGMD2I mouse model that will recapitulate the
clinical phenotypes seen in the majority of LGMD2I pa-
tients without brain involvement.
In an effort to circumvent the problem of embryonic
and neonatal lethality, we adopted RNA interference
(RNAi) technology to postnatally knock down FKRP gene
expression. Specifically, we used adeno-associated virus(AAV) as an efficient and long-term gene delivery vehi-
cle40–48 to deliver short-hairpin RNA (shRNA) to down-
regulate FKRP expression in the skeletal muscles of wild-
type ICR mice. We initially screened for small interference
RNA (siRNA) oligonucleotides and shRNA capable of
effectively knocking down FKRP expression in cultured
cells. Subsequently, the selected shRNA sequences
were cloned and packaged in AAV vectors and then
delivered to the limb muscles of the animals by intramus-
cular injection. Our results showed that specific targeting
of FKRP mRNA by RNAi reduced the level of FKRP tran-
scripts in the skeletal muscle. Furthermore, long-term
down-regulation of FKRP expression also resulted in hy-
poglycosylation of -dystroglycan. AAV-shFKRP-vector–
treated mice developed signs of chronic pathological
changes associated with muscular dystrophy in limb
muscles. Thus, postnatal knockdown of FKRP gene ex-
pression by means of AAV-mediated long-term transfer of
shRNA is a useful approach for generating an LGMD2I
mouse model and investigating the function of FKRP.
Materials and Methods
Cell Culture and Transfection
Both Hepa 1–6 cells (a C57L mouse hepatoma cell line)
and the 293 cells (a human embryonic kidney cell line)
were grown in Dulbecco’s modified Eagle’s medium (In-
vitrogen, San Diego, CA) with antibiotics (penicillin and
streptomycin; Invitrogen) and 10% heat-inactivated fetal
bovine serum (HyClone, Thermo Scientific, Waltham,
MA). For 293 cells, before the transfection, the density of
cells was allowed to reach 80% to 85% in six-well culture
plates. In each well, the transfection was followed by
Lipofectamine with plus reagent method (Invitrogen). A
total of 2 g of plasmid DNA were applied to each well.
After a 48-hour incubation, the protein was extracted and
kept at -20°C for future testing.
For Hepa 1–6 cells, the transfection was preceded by
the DharmaFECT 1 method (Thermo Scientific). Briefly,
the Hepa 1–6 cells were cultured to 80% confluence and
trypsinized with trypsin-EDTA (Invitrogen) and counted;
5  105 cells were remixed with the mixture of siRNA
(Integrated DNA Technologies) and the DharmaFECT 1
reagent. The final siRNA concentration per well was 100
nmol/L for 2.5  105 cells (24-well plate). It was incu-
bated in a 37°C/5% CO2 incubator for 48 hours. After the
first 24 hours of incubation, the medium was aspirated
from the cells and replaced with 500 L of fresh growth
medium. The total RNA was extracted and kept at -80°C
for further assay. All samples were prepared at least in
triplicate, and the results were confirmed by independent
experiments.
Construction of Plasmids Expressing Short-
Hairpin RNAs
All of the FKRP inhibitory 19-mer siRNA (total, 10 candi-
dates) were designed as shRNA forms and cloned into
an AAV vector driven by mouse RNA polymerase III pro-
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mercial plasmid-pSilencer 1.0. The sequence TTCAA-
GAGA was used as the loop of shFKRP.49 For the FKRP2
shRNA construct, the sense (5=-GATCCCCGCAC-
TTCTGTCCCGCTTCATTCAAGAGATGAAGCGGGACA-
GAAGTGCTTTTTGGA-3=) and antisense (5=-AGC-
TTCCAAAAAGCACTTCTGTCCCGCTTCATCTCTTGAAT
GAAGCGGGACAGAAGTGCGGG-3 =) strands of
shFKRP2 were designed with BamH I and HindIII re-
striction site linkers flanking the 5= and 3= termini of
shRNA, respectively. Two oligos of 62 nucleotides,
sense and antisense strands of the shRNA, were synthe-
sized by Integrated DNA Technologies. The annealed
shFKRP2 was cloned into the BamH I and HindIII sites on
the double-stranded AAV vector plasmid containing the




T T C C G A G T A C A T C T C T T G A A T G T A C T C G G A A -
GAAGTCGCGGG-3=) strands of shFKRP5 were also
cloned to the AAV vector. To test the additional effects of
shFKRP2 and shFKRP5, a head-to tail dual-cassette vec-
tor (pAAV-U6-shFKRP2-U6-shFKRP5) was also con-
structed. A control vector pAAV-U6-shGFP has been de-
scribed previously.48 The 19-mer shRNA target
sequence for GFP was 5=-CGGCCACAAGTTCAGCGTG-
3=. Another vector containing a randomly scrambled
shFKRP sequence, 5-TTCGGCTACTCACCGAGTA-3=,
was used as an in vivo control vector.
AAV Vectors Production
The recombinant viral vector stocks were produced ac-
cording to the three-plasmid cotransfection method.50
Briefly, the viral particles were purified twice through a
CsCl density gradient ultracentrifugation using the pre-
viously published protocol.51 The vector titers of viral
particle numbers were determined by the viral DNA dot
blot method. The concentration of viral vectors was
kept in the range of 2  1012 to 5  1012 vector
genomes/ml. storage at -80°C for future use. The final
vectors were named AAV6-shFKRP2, AAV6-shFKRP5
(single cassette), and AAV6-shFKRP2  5 (dual cas-
sette).
Mice and Vector Administration
All protocols involving animal experiments were ap-
proved by the University of North Carolina Animal Care
and Use Committee. ICR mice were purchased from the
Jackson Laboratory (Bar Harbor, ME). The AAV serotype
6 shFKRP vectors were injected into two sites, the tibialis
anterior (TA) and the gastrocnemius (GAS) muscles of
both hind legs of anesthetized 6- to 8-week-old ICR mice
(10 mice/group) with 30 and 100 L (total, 3  1010 and
1  1011 vg) at each site, respectively.42 The shRNA of
the single-cassette groups (FKRP2, 5) and the dual-cas-
sette group (shFKRP2  5) vectors were all driven by
RNA polymerase III promoter U6.Western Blotting
Western analysis was carried out according to a previ-
ously published method.43,52 Briefly, frozen GAS muscle
sections were homogenized with 500 L of ice-cold 1%
TX-100 buffer (50 mmol/L Tris, pH 8.0, 150 mmol/L NaCl,
1% Triton X-100, and 0.1% SDS) supplemented by pro-
tease inhibitor cocktail (Roche, Indianapolis, IN). The
mixtures were centrifuged at 18,000  g at 4°C for 15
minutes to remove the cell debris. The supernatants were
then cleaned using Micro Bio-Spin 6 columns (Bio-Rad
Microscience, Hercules, CA), and the protein concentra-
tion was determined by Bio-Rad DC Protein assay. Of the
total muscle protein, 85 mg were loaded on precast 4% to
20% Tris-glycine gel (Invitrogen) and transferred to poly-
vinylidene (PVDF) membranes. The membranes were
blocked with Pierce Protein-Free T20 Blocking Buffer
(Thermo Scientific) at room temperature for 1 hour. West-
ern blots were performed using the following primary
antibodies at predetermined dilutions: -DG mouse
monoclonal IIH6 (Millipore, Billerica, MA; 1:1000)29; -DG
rabbit polyclonal DAG1 (Sigma-Aldrich, St. Louis, MO,
D1945, 1:4000); actin: rabbit polyclonal anti-actin (Sigma
A2066, 1:1000). Primary antibodies were diluted in 1
TBST (20 mmol/L Tris, pH7.4, 150 mmol/L NaCl, 0.1%
Tween20) with 0.5% gelatin. Blots were incubated with
the antibodies overnight at 4°C. After washing 6  10
minutes with buffer, blots were incubated with goat anti-
mouse IgM (Millipore) or anti-rabbit IgG secondary anti-
bodies (BioRad, Hercules, CA) at room temperature for 1
hour. Membranes were then washed 6  10 minutes with
buffer before developing with ECL kit (Amersham Corp.,
Arlington Heights, IL). Images were taken and processed
using the Fuji LAS-3000 Imaging System.
Real-Time Polymerase Chain Reaction
The RNA from the tissues of interest as isolated by the Trizol
method (Invitrogen) and about 2 g of the total RNA were
reverse transcripted using a high-capacity cDNA reverse
transcription kit (Applied Biosystems, Foster City, CA).
Quantitative real-time polymerase chain reaction (RT-PCR)
was performed on the 7300 RT-PCR system (Applied Bio-
systems) by using the TaqMan gene expression kit (Applied
Biosystems). For each reaction, 2 L of cDNA were used as
a template in the PCR reaction mix, which contained 12.5
L Universal PCR Master Mix (Applied Biosystems); 9.25
L RNase-free H2O; and the 1.25 L primer/probe mixture.
The primer and probe for the FKRP (Mm00557870_m1)
gene expression assay were purchased from Applied Bio-
systems, and -glucuronidase (Gusb, Mm00446953_m1)
was chosen as the endogenous control.
Immunofluorescent Staining
The immunofluorescent staining was performed accord-
ing to the previous published protocol.43,53 Cryostatic
sectioning of the GAS muscle tissue was performed at
8-m thickness (Leica, Bannockburn, IL). For immunoflu-
orescence staining, the unfixed muscle cryosections
were immediately blocked in 10% horse serum and phos-
CA-3=
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ing kit MKB-2213 (Vector Laboratories, Burlingame, CA)
at room temperature for 1 hour, respectively. Monoclonal
antibodies against -dystroglycan (IIH6, adapted from
Dr. Kevin P. Campbell) was diluted 1:50 in 2% horse
serum–PBS and incubated with the cryosections for 2
hours at room temperature. After three washes with PBS
(10 minutes/time), the sections were incubated with Cy-
3-labeled anti-mouse secondary antibodies at 1:500 di-
lutions in 2% horse serum-PBS. After three washes, the
samples were mounted in gel-mount aqueous antifading
medium (Fisher, Pittsburgh, PA). Photographs were taken
with a Nikon Eclipse TE300 microscope, using a Spot RT
Slider digital camera (Diagnostic Instruments, Inc., Ster-
ling Heights, MI).
Laminin Ligand Overlay Assay
On a basis of a paper published by Michele and col-
leagues,54 ligand overlay assays were performed on
PVDF membranes using mouse Engelbreth-Holm-Swarm
laminin (Sigma). Briefly, PVDF membranes were blocked
in laminin-binding buffer (LBB) (10 mmol/L triethano-
lamine, 140 mmol/L NaCl, 1 mmol/L MgCl2, 1 mmol/L
CaCl2, pH 7.6) containing 5% nonfat dry milk followed by
incubation of each ligand overnight at 4°C in LBB. Mem-
branes were washed and incubated with antilaminin
(Sigma) followed by anti-rabbit IgG-HRP. Blots were de-
veloped by enhanced chemiluminescence.
Solid-Phase Assay
Wheat germ agglutinin (WGA) eluates were diluted 1:50
in TBS and coated on polystyrene ELISA microplates
(Corning Costar, Lowell, MA) for 16 hours at 4°C. Plates
were washed in LBB and blocked for 2 hours in 3%
bovine serum albumin in LBB. Mouse Engelbreth-Holm-
Swarm laminin was diluted in LBB and applied for 2
hours. Wells were washed with 3% bovine serum albumin
in LBB, incubated for 30 minutes with 1:10,000 anti-lami-
nin (Sigma) followed by anti-rabbit horseradish peroxidase.
Plates were developed with o-phenylenediamine dihydro-
chloride and H2O2; reactions were stopped with 2N H2SO4;
and values were obtained on a microplate reader. The data
were analyzed by the equation A  Bmax  (Kd  ), where
K is the dissociation constant, A is absorbance, and B












is maximal binding.Myofiber Size Measurement
The measurement of the myofiber size in our study was
done according our previously published protocol.55 We
subjected 8-m cryo-thin sections of the GAS muscles to
immunofluorescence (IF) staining against the laminin-2
to display the circumferences of the myofibers. Pictures
were taken and the radius of the myofiber was analyzed
by using Metamorph software with a minimum of 300
myofibers from each mouse and at least three mice in
each group.
Results
In Vitro Screening of FKRP siRNA
Oligonucleotides
Small-interference RNA design requires optimization of
candidate sequences. We selected 10 potential target
sequences against the mouse FKRP mRNA. The mouse
FKRP gene (GenBank NM 173430) contains two noncod-
ing exons (exon 1 and 2) and a 2.7-kb coding exon (exon
3). The exon 3 consists of 5= untranslated region (5=-
UTR), the open reading frame, and the 3=-UTR. All 10
siRNAs (FKRP1-10) were designed to target exon 3, with
FKRP1 through FKRP4 targeting the 3=-UTR, whereas
FKRP5 through FKRP10 targeted the coding sequence
(Table 1). To perform a pilot screening on the efficiencies
of RNAi-mediated FKRP knockdown, we synthesized four
pairs of siRNA oligos against 4 of the 10 target se-
quences. The four duplex siRNA oligos (siFKRP1,
siFKRP2, siFKRP3, and siFKRP5) were transfected into
mouse Hepa 1–6 cell line that expresses FKRP. Quanti-
tative RT-PCR on RNA isolated at 2 days post-transfec-
tion of siFKRP1 and siFKRP3 demonstrated approxi-
mately a 60% and a 37% reduction of FKRP mRNA,
respectively, compared to the controls (see Supplemen-
tal Figure 1 at http://ajp.amjpathol.org). Meanwhile,
siFKRP2 and siFKRP5 each achieved about 70% knock-
down efficiency, whereas co-transfection of both siRNA
oligos into Hepa 1–6 cells led to a nearly 80% reduction
of FKRP mRNA. These results demonstrated that the use
of two effective siRNA oligos together enhanced FKRP
knockdown efficiency, which would make a significant


















TG-3=difference in our subsequent experiments in vivo.
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Their Efficiency
Because the synthetic siRNA oligos FKRP2 and FKRP5
showed the highest knockdown efficiency, we separately
subcloned each sequence in the form of an shRNA gene
into an AAV vector expression plasmid. The resulting plas-
mid constructs were referred to as pAAV-U6-shFKRP2 and
pAAV-U6-shFKRP5 (Figure 1A). The expression cassette
was under the control of a mouse U6 promoter and there-
fore had an advantage over the synthetic siRNA in long-
term expression.48 Because of the positive effect of co-
transfecting both siRNA oligos, a dual-cassette vector
pAAV-U6-shFKRP2  5 containing both shFKRP2 and
shFKRP5 expression cassettes was also constructed (Fig-
ure 1A). We then examined whether plasmid transfection of
our designed plasmid AAV FKRP shRNA vectors would
yield similar knockdown efficiencies of the FKRP gene com-
parable to the synthetic siRNA oligos in Hepa 1–6 cells.
Quantitative RT-PCR was performed using the RNA sam-
ples isolated from the transfected Hepa 1–6 cells at 48
hours post-transfection. As shown in Supplemental Figure
S2A (http://ajp.amjpathol.org), pAAV-U6-shFKRP2 achieved
a knockdown efficiency of approximately 60% (42.6% 
12% FKRP remaining) comparable to that of FKRP2 siRNA
oligo. In contrast, pAAV-U6-shFKRP5 led to only a 52.7%
reduction of FKRP transcripts (47.3%  4.2% remaining),
which was lower than the nearly 70% knockdown efficiency
obtained by the FKRP5 siRNA oligo. The dual cassette
pAAV-U6-shFKRP2  5 resulted in 66% knockdown of
FKRP gene (34.4  13.1% remaining). Cotransfection of
pAAV-U6-shFKRP2 and pAAV-U6-shFKRP5 also resulted in
similar knockdown efficiency at roughly 65% (35.6% 
14.5% remaining). Altogether, the effects of the plasmid
vectors of AAV-shRNA, especially the dual cassette plas-
Figure 1. Design and testing of the constructs of recombinant adeno-asso-
ciated viral vectors expressing the shRNA against FKRP. A: Schematic of
pAAV-U6-shFKRP vectors. The FKRP2 and FKRP5 expression cassettes in the
dual cassette lie in a head-to-tail orientation. The EYFP-tagged mouse FRKP
plasmid was driven by the CMV promoter. B: Knockdown of FKRP-EYFP
protein synthesis shown by Western analysis of 293 cells cotransfected with
pFKRP-EYFP and pAAV-U6-shFKRP plasmids. FKRP-EYFP fusion protein,
with a molecular weight of about 100 kDa, was detected by anti-GFP anti-
body, which cross-reacts with EYFP. Actin was stained as a sample loading
control. Samples were prepared in duplicate.mid on FKRP transcripts, were largely consistent with thoseof synthetic siRNA oligos (compare Supplemental Figure
S2A with Supplemental Figure S1 at http://ajp.amjpathol.
org). Subsequently, we also cloned the remaining six
shRNAs (FKRP4, 6–10; see Table 1) into the pAAV-U6
backbone for shRNA expression and examined all 10 sin-
gle-cassette shRNA plasmids side-by-side for their FKRP
mRNA knockdown activities after transfection and quantita-
tive RT-PCR. Among the six new constructs, only pAAV-U6-
shFKRP9 achieved significant knockdown (59.2%  7.1%
remaining), which was still less effective than pAAV-U6-
shFKRP2 or pAAV-U6-shFKRP5 (data not shown).
Next we investigated the effects of FKRP knockdown
on FKRP protein synthesis. Given that endogenous FKRP
was difficult to detect,21,56 we had previously engineered
a construct pFKRP-EYFP encoding mouse FKRP and a
C-terminal fusion of enhanced yellow fluorescent protein
(EYFP) (Figure 1A). The FKRP-EYFP fusion was used as
an indirect indicator of FKRP protein after knockdown by
plasmid vectors of AAV-shRNA. Cotransfection of
pFKRP-EYFP expression plasmid and pAAV-U6-FKRP
vectors was carried out in the 293 cell line. The FKRP-
EYFP protein was monitored by fluorescent microscopy
and Western blot. Our results showed that the intensity of
EYFP fluorescence in the cotransfected cells was signif-
icantly reduced by pAAV-U6-shFKRP5 and the dual-cas-
sette pAAV-U6-shFKRP2  5 compared to cells trans-
fected with pFKRP-EYFP only (see Supplemental Figure
S2B at http://ajp.amjpathol.org). Similar results were ob-
served on Western blots of the cotransfected cells using
an anti-GFP antibody that cross-reacts with EYFP (Figure
1B). On the other hand, pAAV-U6-shFKRP3 had no ef-
fects (Figure 1B, and see Supplemental Figure S2B at
http://ajp.amjpathol.org). It is important to mention that the
pFKRP-EYFP reporter did not contain the 3=-UTR of FKRP
mRNA and thus can be targeted only by AAV vectors
containing the shRNA5 sequence. The apparently more
effective inhibition by shRNA5 on the reporter FKRP-
EYFP fusion protein (Figure 1B) than on the endogenous
FKRP mRNA (see Supplemental Figure S2A at http://
ajp.amjpathol.org) is likely to be due to the co-entry of the
shRNA5 plasmid and its target FKRP-EYFG plasmid into
the same cotransfected cells. On the other hand, inhibi-
tion of the endogenous FKRP mRNA in Hepa 6-1 cell line
is heavily dependent on the percentage of cells trans-
fected by the shRNA plasmid. In summary, our findings
showed that pAAV-U6-shFKRP2  5 was able to sup-
press FKRP expression effectively and to reduce its
mRNA and the protein.
Effective FKRP Knockdown in Adult Mouse
Muscle by AAV shRNA Vectors
To examine the effects of the shFKRP in vivo, we pack-
aged the U6-shFKRP2, the U6-shFKRP5, and the dual-
expression cassette U6-shFKRP2  5 into the AAV sero-
type 6 (AAV6) vector for effective gene transfer in the
skeletal muscles by local intramuscular injection.57–60
Lower hind-leg muscles (GAS and tibalis anterior [TA]) of
2-month-old ICR mice (n  10) were injected intramus-
cularly with the respective AAV vector or control PBS
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trol muscles were collected at 2 months and 10 months
later (n  5 in each time point) for analyses of FKRP
expression as well as of dystrophic pathology. Quantita-
tive RT-PCR was performed using RNA samples ex-
tracted from the GAS muscles. At 2 months and 10
months after injection, the single-cassette shFKRP2 re-
duced FKRP expression by 10.6%  10.8% and 46.5% 
4.1%, respectively, when compared to the PBS-treated
GAS muscles (Figure 2). Meanwhile, the single-cassette
shFKRP5 attained a knockdown efficiency of 48.3% 
10.1% (2 months) and 45.0%  7.4% (10 months). In
contrast, the dual-cassette shFKRP2  5 achieved 71.6%
 2% and 72.3%  7.8% knockdown of FKRP expression
at the two time points (Figure 2). The observations that
the dual cassette was more effective than the single
cassette in knocking down FKRP gene expression was in
agreement with our previous results of screening siRNA
and shRNA in cell cultures. It remains unclear why
shFKRP2 at 2 months after injection attained only a 10%
knockdown.
FKRP Knockdown in Adult Mouse Muscle
Caused Dystrophic Pathology
When we examined the AAV-treated mice, we noticed
that muscle pathology was essentially absent at 2 months
after AAV U6-shFKRP treatment and was indistinguish-
able from both of the PBS-treated controls (Figure 3A,
left panels) and from the scrambled control muscles
(see Supplemental Figure S3, upper row, at http://ajp.
amjpathol.org). Although quantitative RT-PCR of the same
muscle samples showed the highest reduction of FKRP
expression by the dual-cassette shFKRP2  5 (Figure 2),
the mice apparently did not develop dystrophic pheno-
Figure 2. Analysis of FKRP mRNA knockdown in GAS muscles after intra-
muscular injection of AAV6 shFKRP vectors. At the 2-month time point,
quantitative RT-PCR analyses of FKRP mRNA in the muscle samples showed
significant knockdown in groups treated with shFKRP5 (48.3  10.1%) and
shFKRP2  5 (71.6  1.2%) but not in the group treated with shFKRP2
(10.6  10.8%). However, at the 10-month time point, FKRP mRNA was
knocked down in all AAV-treated groups, shFKRP2 (46.4  4.1%), shFKRP5
(45.0  7.4%), and dual shFKRP2  5 (72.3%  7.8%) (n  5, mean  SD;
* P  0.05).types. It is striking that at 10 months after AAV treatment,both the TA and GAS muscles of these mice were found
to contain large number of myofibers with centrally local-
ized nuclei (CN), a hallmark of muscle degeneration and
regeneration (Figure 3A, right panels). However, muscles
treated with the single-cassette AAV vector, either
shFKRP2 or shFKRP5, showed only minimal signs of pa-
thology, displaying much fewer centrally nucleated myo-
fibers (Figure 3, A, right panels). Masson trichrome stain-
ing was also performed on GAS muscles from each
group 10 months after injection to detect signs of fibrosis.
Our findings demonstrated that deposition of connective
tissues was more prominent in the GAS muscles of the
shFKRP2  5–treated mice than the other two single-
cassette–treated mice or the control group treated with
PBS (Figure 3B). Altogether, these results suggest that a
Figure 3. Analysis of the muscle fiber pathology and morphology. GAS and
tibialis anterior muscles transduced with AAV6-shFKRP were collected 2
months and 10 months postinjection. A: Cryo-thin sections of the muscle
samples were analyzed using H&E staining. Similar pathological signs in the
GAS and TA muscles were observed in both AAV-treated and PBS-injected
groups at 2 months postinjection. Note that more centrally nucleated myo-
fibers were found in the shFKRP2  5–treated muscle at 10 months postin-
jection (arrows). Scale bar, 100 m. B: Increase of connective tissue depo-
sition in the shFKRP-treated muscle. Masson trichrome staining was
performed on the cryo-thin section of GAS muscles from each treatment
group at 10 months postinjection. Note that connective tissues were fre-
quently found in the intermediate of myofibers (arrows) in both single- and
dual-cassette shFKRP-treated groups. Scale bar, 100 m.
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75% in the normal muscle is sufficient for the mice to
develop progressive dystrophic pathology between 2
and 10 months. The phenotypes of our FKRP knockdown
mice are consistent with the mild pathology and late-
onset progression commonly observed in patients with
LGMD2I.
To further explore this issue, quantitative analysis of
the myofibers showed a CN rate of 51.0%  8.5% in the
dual-cassette shFKRP2  5–treated group, which was
much higher than the PBS-treated control group of 1.0%
 0.5% (Figure 4A, t-test P  0.001). Although the U6-
shFKRP2–treated muscles showed a CN rate of 12.1% 
3.3%, which was statistically higher than the PBS-treated
group, the overall rate of CN in the single-cassette
shFKRP-treated muscles was still significantly lower than
that observed in the shFKRP2  5–treated group (Figure
4A). Subsequently, quantitative analysis of the myofiber
radius revealed a much broader distribution of fiber size
(more smaller and larger myofibers) in shFKRP2 
5–treated muscles (Figure 4B), suggesting chronic mus-
cle degeneration and regeneration. Finally, we also mon-
itored serum creatine kinase (CK) levels because the
vector-injected dystrophic limb muscles could release
CK systemically. Indeed, we found that the serum CK
activities in mice that were treated with the shFKRP5
(1480.4  214.4 IU/L) and the dual shFKRP2  5 (2104 
675.7 UI/L) were significantly higher than those of the
control mice (884.1  214.5 IU/L) (Figure 4C). The ele-
vated serum CK levels are in agreement with the dystro-
phic pathology of the vector-treated limb muscles.
FKRP Knockdown in Adult Mouse Muscle
Resulted in Hypoglycosylation of
-Dystroglycan
It has been reported that FKRP mutations often lead to
secondary defects in -dystroglycan glycosylation, that
is, hypoglycosylation.20,30–33 The monoclonal antibody
IIH6 specifically recognizes the glycosylated epitopes on
-DG61–63 and was often used to detect abnormal gly-
cosylation of -DG in the muscle samples of patients
having LGMD2I.13,31–33 We therefore used this antibody
to examine whether hypoglycosylation of -DG occurred
in AAV U6-shRNA–treated muscles as a result of FKRP
knockdown. First, immunofluorescent staining was per-
formed on cryo-thin sections of the GAS muscles that
were collected 10 months after treatment. The GAS mus-
cle from mdx mice was used as a negative control be-
cause it lacks -DG at the sarcolemma.64 When muscle
sections were labeled with the IIH6 antibody, the immu-
nofluorescent signal of AAV-U6-shRNA–treated muscles
was noticeably reduced in comparison to the PBS-
treated muscles, suggesting aberrant modification of
-DG as a result of FKRP knockdown (Figure 5A).
The reduction of signal was especially apparent in the
dual-cassette shFKRP2  5–treated muscle. Further-
more, Western blots were performed using proteins ex-
tracted from the GAS muscle of each treatment group
(Figure 5B). Consistent with the immunofluorescent re-Figure 4. Quantification of the muscle fibers’ pathology and morphology. A:. The
numbers of centrally nucleated fibers in AAV-shFKRP-treated TA and GAS muscles
were counted in five random fields of view under the microscope. In both TA and
GAS muscles, not only the single-cassette groups treated with shFKRP2 (6.3% 
1.4% and 12.1%  3.3%) and shFKRP5 (3.1%  0.9% and 8.7%  2.8%), but also the
dual-cassette group treated with shFKRP2  5 (49.4%  4.9% and 51.1%  8.5%)
showed centrally nuclear myopathy that was significantly different from that of the
control group (2.0%  1.05% and 1.01%  0.48%, n  5, mean  SD, *P  0.001).
B: The radius of individual GAS myofibers in each treatment group was measured
and evaluated by MetaMorph software. Note that the shFKRP2  5–treated GAS
muscles (black column) displayed more variable and uneven distribution of myo-
fiber radius than did the PBS-treated muscle (white column) (n  5, mean  SD,
Student’s t-test, *P  0.001; **P  0.05). C: The level of creatine kinase (CK) in each
treatment group was analyzed. Note that compared with the control (884.1  214.5
IU/L; white column), the levels of CK in shFKRP2  5–treated mice (2104  675.7
UI/L; black column) and in shFKRP5 (1480.4  214.4 IU/L; diagonal column)
were significantly increased (n  5, mean  SD, *P  0.001).
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molecule weight for -DG was observed in all AAV-
shFKRP–treated muscles (Figure 5B, lanes 3–6). The
other component of the dystroglycan, -dystroglycan (-
DG), was also monitored by Western blot. As expected,65
there was no reduction of -DG in all AAV-treated muscle
when compared to saline control muscle except muscle
from the mdx control, which has been well documented to
have much reduced dystroglycans due to dystrophin de-
ficiency. These results suggest that the shKFRPs did not
inhibit dystroglycan gene expression, that is, precursor
mRNA and protein synthesis; but the shFKRPs did sig-
nificantly affect and reduce the level of the fully glycosy-
lated -DG.
Furthermore, we performed the ligand overlay assay
and solid-phase assay using laminin on a blot of WGA-
enriched shFKPR knockdown muscles (Figure 5, C and
D). In muscles from the shFKRP2  5 group, the ligand
binding activities were markedly reduced, similar to those
of the dystrophin-deficient mdx mouse group, and much
lower than those of the saline-treated and scrambled-
vector–treated control groups (Figure 5C). To quantify the
total ligand-binding activity of intact (nondenatured)
-DG, we performed solid-phase laminin-binding assays
of WGA-enriched protein fractions from the same muscle
samples (Figure 5D). The total high-affinity laminin-bind-
ing activity in the shFKRP2, shFKRP5, and shFKRP2  5
group was reduced by approximately 50%, 60%, and
70%, consistent with the data from the laminin overlay
assay (Figure 5C). These results suggest that the re-
duced laminin-binding activity in the FKRP knockdown
muscles are likely to be caused by the reduced glycosy-
lation of -DG.Discussion
LGMD2I was originally reported in a Tunisian family.19
Patients who have LGMD2I with mutations in the FKRP
gene usually manifest mild muscular dystrophy with late
onset and no central nervous system abnormalities. How-
ever, FKRP mutations can also cause more severe and
early-onset congenital muscular dystrophy, muscular
dystrophy type 1C, and muscle-eye-brain disease. De-
spite the recent gains in knowledge about LGMD2I and
FKRP, there is still a lack of a representative animal model
that recapitulates LGMD2I phenotypes. The classical
gene knockout approach resulted in embryonic lethality
in mice when the FKRP gene was completely ablated. To
overcome this problem, genetic knockin of the mutant
human FKRP gene has been investigated in other stud-
ies. Disease-causing missense mutations, for example
L276I and Y307N, were engineered in mice, anticipating
that these mutations would cause phenotypes character-
istic of human patients. However, these mice often did
not generate phenotypes unless the neomycin selection
cassette was present in the mutant FKRP allele,37 which
reduced FKRP transcripts and also caused a severe
muscle-brain-eye phenotype. A recent study by our
group showed that homozygous knockin of a missense
P448L mutation also manifested severe muscle-brain-eye
phenotypes, but some homozygous mice were viable to
adult age.66 In order to avoid disrupting embryonic de-
velopment and complications in the central nervous sys-
tem, we used RNAi technology to effectively knockdown
FKRP gene expression in normal adult mouse muscle via
AAV-mediated postnatal gene transfer. Intramuscular in-
Figure 5. Abnormal glycosylation of -dystro-
glycan in shFKRP-treated muscles after 10
months. A: Immunofluorescent staining of the
AAV-shFKRP-treated GAS muscles with -dystro-
glycan–specific antibody IIH6 at 10 months
postinjection. Note the reduction of staining in
the shFKRP2  5–treated muscles. B: Western
blot of proteins extracted from GAS muscles of
each treated group were done using anti--dys-
troglycan (IIH6) and -dystroglycan (DAG-1) an-
tibodies to evaluate the glycosylation of -dys-
troglycan and the expression of -dystroglycan,
respectively. The GAS muscles from mdx mice
and PBS-treated mice were used as the negative
and positive controls, respectively. C: A ligand
overlay assay using laminin on a blot of WGA-
enriched shFKPR knockdown muscles was per-
formed. Note that the affinity of the -dystrogly-
can to laminin in shFKRP2  5–treated muscles
(lanes 6 and 7) was weaker than in the control
group (lane 2). D: Solid-phase assays were per-
formed to quantitate the maximum laminin bind-
ing ability to -DG in the shFKRP-treated mus-
cles. Note that the binding ability of -DG in
shFKRP2 (53.7%  5.0%); -5(40.6%  4.4%); and
-2  5 (31.0%  3.0%) treated groups was de-
creased and weaker than in the control group (n
 5, mean  SD, *P  0.001.)jection of AAV shFKRP to the hind leg muscles of adult
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gene knockdown, resulting in a progressive and mild
dystrophic pathology similar to that observed in patients
having LGMD2I.
In the first part of our study, we selected 10 potential
target sites (Table 1) on the mouse FKRP gene to screen
for the most effective siRNA sequences. Four randomly
selected siRNAs in duplex forms were synthesized and
tested in an FKRP-expressing cell line Hepa 1–6. Two of
the four synthetic siRNAs (FKRP2 and FKRP5) were
shown to have the best knockdown efficiency, approxi-
mately 70% to 80% (see Supplemental Figure S1 at
http://ajp.amjpathol.org). To take advantages of the long-
term effects of AAV-mediated gene transduction in vivo,40–
46,67 we cloned the two most effective siRNA sequences
into an expression vector driven by the U6 promoter in
either single- or dual-expression cassettes. It is worth
mentioning that the shFKRP expression constructs
seemed to be less effective in the transfection experi-
ments when compared to the synthetic siRNAs (compare
Supplemental Figure S1 and Supplemental Figure S2A at
http://ajp.amjpathol.org). In addition to the possibility of
transfection-efficiency differences between the oligos
and plasmids, their structural differences might also con-
tribute to their biological activities. The synthetic siRNA
forms an open-ended duplex, whereas the AAV-shRNA
takes the shape of a short hairpin. The latter requires
additional enzymatic processing in the cells and there-
fore might not behave in the same way as the synthetic
counterpart in some cases (for example, siFKRP1 vs.
shFKRP1, in Supplemental Figure S1 and Supplemental
Figure S2A at http://ajp.amjpathol.org).
Adeno-associated virus-based vectors are well docu-
mented for their ability to provide efficient and long-term
gene delivery to the muscles.43,48,68,69 AAV vector-medi-
ated gene delivery of shRNA has been used to success-
fully knockdown dystrophin expression in mouse skeletal
muscle.60 Suppression of dystrophin expression was
maintained for up to 1 year. It is interesting that no dys-
trophic pathology was observed in these mice. Dickson
and colleagues60 have discussed a number of possible
reasons for this finding, including the long half-life of
dystrophin protein. Another reason that might account for
the failure to induce dystrophic pathology in normal mice
might be directly related to the residual amount of dys-
trophin that escaped shRNA-mediated knockdown. Pre-
vious transgenic mouse studies showed that 10% of the
normal dystrophin expression would be sufficient to pre-
vent dystrophic pathology in mdx mice,70 suggesting that
more than a 90% knockdown of the normal level of dys-
trophin expression is required to cause dystrophic phe-
notypes. In another study, we reported that AAV-
mediated shRNA knockdown in TA muscle caused ap-
proximately 70% down-regulation of A-type lamin at 2
weeks postinjection and generated phenotypes reminis-
cent of neuromuscular junction defect.48 These studies
indicated that there might be a threshold for the minimal
amount of the knockdown gene required for function in
each disease model.
Our study might provide clues about how much reduc-
tion of FKRP expression would be necessary to generatedystrophic phenotypes. When the single-expression cas-
sette shFKRP (shFKRP2 or shFKRP5) was delivered to
the muscle via AAV6, nearly 50% reduction of FKRP gene
expression was observed. However, a near 75% reduc-
tion in FKRP gene expression was reached by the dual-
cassette shFKRP2  5 (Figure 2). In fact, the dual cas-
sette has consistently achieved the highest knockdown
efficiency in both cell cultures and muscle, suggesting an
additive effect. The 75% knockdown of the FKRP gene
expression was apparently sufficient to induce overt dys-
trophic pathology in the treated muscles 10 months after
injection (Figure 3A). Approximately one half of the myo-
fibers showed centrally localized nuclei (Figure 4A); the
morphology of the myofibers was smaller and more un-
even (Figure 4B); and the serum CK was 2.5-fold of
normal controls (Figure 4C). On the other hand, very
limited pathology and much fewer centrally localized nu-
clei were observed in the single-cassette shRNA-treated
muscles, despite a nearly 50% knockdown of FKRP gene
expression by the single cassette shFKRP for the same
period. It should be noted that the percentage of knock-
down determined by quantitative RT-PCR represented an
average of all of the myofibers in the tissue that was used
to extract the RNA. We suspect that the small number of
myofibers with central nucleation in the single-cassette–
treated muscle was the result of extra-high uptake of the
vector by a small number of myofibers near the needle
track of intramuscular injection. The extra-high vector
uptake would lead to more effective knockdown, suffi-
cient to induce limited pathology even in the cases of the
single shFKRP cassette. However, the majority of the
myofibers a distance from the needle track might not
have the extra-high expression needed to achieve suffi-
cient FKRP knockdown, given that the single shFKRP was
not as potent as the dual shFKRP2  5. This could offer
a plausible explanation for the low-level central nucle-
ation in the single-cassette shFKRP2- and shFKRP5-
treated muscles. By the same token, the uneven nature of
vector in intramuscular injections should be taken into
consideration when interpreting data.
These observations suggest that a reduction of ap-
proximately 75%, but not 50%, of the normal level of
FKRP expression induces overt dystrophic pathology.
This could provide useful guidance and help to narrow
the range or threshold of effectively therapeutic restora-
tion of the FKRP, which we believe is in the neighborhood
of 25% of the wild-type levels. It is clearly important to
take this value into consideration when designing gene
therapy and small-molecule drug therapy such as stop
codon read through. However, because of the lack of an
antibody to detect endogenous FKRP, either by immuno-
fluorescent staining or by Western blot, we were unable
to determine the level of FKRP protein in the knockdown
muscles. As a result, our data concerning FKRP expres-
sion were indirectly based on quantitative RT-PCR of
mRNA.
Another important finding in our FKRP knockdown
mice was the development of progressive and relatively
mild pathology, despite the fact that FKRP gene expres-
sion was strongly suppressed at young adulthood. When
we examined the hind-leg muscles (GAS and TA) 2
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RT-PCR showed that FKRP gene expression was signif-
icantly reduced as much as 70%. However, we did not
detect apparent muscle pathology in the mice until 10
months of age. This observation is in line with the mild
phenotypes and late onset seen in patients with LGMD2I.
It will be of interest to investigate whether other genes in
the knockdown muscle are compensating for FKRP defi-
ciency during the course of disease development.
The function of FKRP is not clearly understood, but it is
thought to play an important role in the post-translational
modification of -DG. Consistent with this hypothesis,
glycosylation of -DG was indeed much reduced in the
FKRP knockdown muscles, as revealed by the presence
of IIH6 antibody, specific for the polysaccharide side
chain (Figure 5B). Three lines of evidence unequivocally
point to the reduction of -DG glycosylation in knock-
down of FKRP expression. First, the protein quantity of
-DG, which shares the same mRNA and protein precur-
sor with -DG, was not reduced other than slightly in-
creased as shown by Western blot (Figure 5B). Second,
quantitative PCR of dystroglycan mRNA transcripts did
not reveal appreciable alteration in any of the muscles
(data not shown). Third, and most important, the laminin-
binding activity of the -DG in the shFKRP-treated mus-
cles as reduced in both the ligand binding assay (Figure
5C) and solid-phase assay (Figure 5D). Thus, the re-
duced detection of -DG by IIH6 antibody was not
caused by reduction of dystroglycan gene expression. It
is interesting that the molecular weight of the -DG in the
FKRP knockdown muscles was unchanged, unlike the
evident reduction on the molecular weight of -DG seen
in some patients with FKRP missense mutations. A pos-
sible explanation is that certain mutant FKRP proteins
may exhibit altered enzymatic properties, which incor-
rectly glycosylate the -DG. On the other hand, shRNA
knockdown of FKRP reduced the quantity but not the
property of the enzyme. Thus, reduced amounts of wild-
type FKRP should still be able to correctly and fully gly-
cosylate -DG, although only a fraction of all -DG, re-
sulting in reduced intensity but normal molecular weight
of -DG on Western blot as detected by the IIH6 anti-
body. It has been well documented that -DG interacts
with laminin and plays a critical role in linking the cy-
toskeleton and the extracellular matrix.71,72 In several
clinical reports, the expression of the laminin 2 chain
was found to be lower in the biopsies of patients with
LGMD2I.16,33,73 In our knockdown mice, however, the
level of laminin 2 chain, as judged by immunofluores-
cent staining, had not changed in the treated GAS mus-
cle (data not shown); this could explain the relatively mild
pathology.
This study demonstrated that the expression of FKRP
can be down-regulated by RNAi technology and that
using the AAV vector as a delivery system can achieve
effective and long-term suppression of FKRP gene ex-
pression in vivo. Based on the pathology and progression
of the muscle phenotypes, our mice could be a useful
model for the study of the mild form of LGMD2I.Acknowledgments
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